Abbott’s Deep Brain Stimulation System Receives the US FDA's Breakthrough Device Designation for Severe Depression
Shots:
- The US FDA has granted BTD to investigate the use of its personalized, adjustable therapy i.e., deep brain stimulation (DBS) system for treatment-resistant depression
- Abbott’s DBS system delivers electrical pulses to modify abnormal brain activity and is used to treat the symptoms of people with movement disorders i.e., Parkinson’s disease and essential tremor
- The program aims to give patients and clinicians quick access to these treatments by speeding their development, evaluation, and review while preserving regulatory criteria for pre-market approval. The company is currently working with the US FDA to develop a plan for evaluating the device's safety and effectiveness
Ref: Abbott | Image: Abbott
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
